Active — Not RecruitingPhase 2

Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies With Alpha Beta TCell and B Cell Depletion Using the CliniMACS Device

United States60 participantsStarted 2015-10

Plain-language summary

This is a single arm pilot study for patients with hematologic malignancies with alternative donor sources receiving unrelated or partially matched related/Haploidentical mobilized peripheral stem cells (PSCs) using the CliniMACS system for Alpha Beta T cell depletion plus CD19+ B cell depletion to determine efficacy as determined by engraftment and GVHD, and one year leukemia free survival.

Who can participate

Age range23 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age. Patient age \< 23 years. Both genders and all races eligible.
✓. Disease eligibility

Exclusion criteria

✕. Patients who do not meet disease, organ or infectious criteria.
✕. No suitable donor

What they're measuring

Evaluate the engraftment of patients receiving unrelated donor or partially matched related donor peripheral stem cells that have T cell depleted and CD19+ B cell depleted using the CliniMACS device.

Timeframe: DAY 42

Trial details

NCT IDNCT02600208

SponsorJulie-An M. Talano

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12

View on ClinicalTrials.gov More Hematologic Malignancies trials